)
Overview
<ul>
<li>Instil Bio Q3 net loss per share improves to $2.01 from $3.54 yr/yr</li>
<li>Company’s cash and investments fall to $83.4 mln from $115.1 mln at end of 2024</li>
<li>Research and development expenses rise to $9.1 mln from $0.6 mln yr/yr</li>
</ul>
Outlook
<ul>
<li>Instil expects cash resources to fund operations beyond 2026</li>
</ul>
Result Drivers
<ul>
<li>R&amp;D EXPENSES - Research and development expenses increased to $9.1 mln from $0.6 mln yr/yr, reflecting investment in clinical trials</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Basic -$2.01
<h3>EPS</h3>
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Instil Bio Inc is $88.00, about 83% above its November 12 closing price of $14.99</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Instil Bio's Q3 net loss per share improved to $2.01 from $3.54 year-over-year. The company's cash and investments decreased to $83.4 million from $115.1 million. Research and development expenses rose to $9.1 million from $0.6 million, indicating investment in clinical trials. Analysts rate the stock as a "buy," with a median 12-month price target of $88.00, significantly above the current price of $14.99.

Instil Bio Q3 net loss per share narrows